3-[7,8,9,10-tetrahydro-8-(hydroxymethyl)-6H-azepino[1,2-a]indol-11-yl]-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione | 131848-64-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - Pyrroloazepines
• 英文名称: 3-[7,8,9,10-tetrahydro-8-(hydroxymethyl)-6H-azepino[1,2-a]indol-11-yl]-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione
• 英文别名: 3-[8-(hydroxymethyl)-7,8,9,10-tetrahydro-6H-azepino[1,2-a]indol-11-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione
• CAS: 131848-64-1
• 化学式: C₂₇H₂₅N₃O₃
• 分子量: 439.514
• InChiKey: QVEQQWCIJJDTPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  76.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[7,8,9,10-tetrahydro-8-(hydroxymethyl)-6H-azepino[1,2-a]indol-11-yl]-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione 在 2,4,6-三甲基吡啶 、 ammonium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 3-(8-Aminomethyl-7,8,9,10-tetrahydro-6H-azepino[1,2-a]indol-11-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione
  参考文献：
  名称：

  Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction

  摘要：

  The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competitive inhibitors of improved potency and selectivity. Two compounds have been further evaluated and were shown to inhibit PKC of human origin and prevent T-cell activation in a human allogeneic mixed lymphocyte reaction. One of these compounds was orally absorbed in mice and antagonized a phorbol ester induced paw edema in a dose-dependent manner. This compound also selectively inhibited the secondary T-cell mediated response in a developing adjuvant arthritis model in rats and provides evidence for the potential use of PKC inhibitors as therapeutic immunomodulators.

  DOI：

  10.1021/jm00053a003
• 作为产物：
  描述：

  Acetic acid 11-chlorooxalyl-7,8,9,10-tetrahydro-6H-azepino[1,2-a]indol-8-ylmethyl ester 在 ammonium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 74.0h， 生成 3-[7,8,9,10-tetrahydro-8-(hydroxymethyl)-6H-azepino[1,2-a]indol-11-yl]-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction

  摘要：

  The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competitive inhibitors of improved potency and selectivity. Two compounds have been further evaluated and were shown to inhibit PKC of human origin and prevent T-cell activation in a human allogeneic mixed lymphocyte reaction. One of these compounds was orally absorbed in mice and antagonized a phorbol ester induced paw edema in a dose-dependent manner. This compound also selectively inhibited the secondary T-cell mediated response in a developing adjuvant arthritis model in rats and provides evidence for the potential use of PKC inhibitors as therapeutic immunomodulators.

  DOI：

  10.1021/jm00053a003

文献信息

• 4-\x9b3-indolyl!-1H-pyrrolone
  申请人：Hoffmann-La Roche Inc.

  公开号：US05721245A1

  公开（公告）日：1998-02-24

  A compound of the formula ##STR1## wherein R is hydrogen or hydroxy, R.sup.1 and R.sup.2 taken together are a group of the formula --(CH.sub.2).sub.m -- and R.sup.7 is hydrogen or R.sup.1 and R.sup.7 taken together are a group of the formula --(CH.sub.2).sub.n -- and R.sup.2 is hydrogen; R.sup.3 is an aryl or aromatic heterocyclic group; R.sup.4, R.sup.5 and R.sup.6 each independently are hydrogen, halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, alkylthio, alkylsulfinyl or alkylsulfonyl; R.sup.8 is a group of the formula --(CH.sub.2).sub.p --R.sup.9 or --(CH.sub.2).sub.q --R.sup.10 ; R.sup.9 is hydrogen, alkylcarbonyl, aminoalkylcarbonyl, cyano, amidino, alkoxycarbonyl, aryloxycarbonyl, alkylsulfonyl, aminocarbonyl or aminothiocarbonyl; R.sup.10 is hydroxy, alkoxy, halogen, amino, monoalkylamino, dialkylamino, trialkylamino, azido, acylamino, alkylsulfonylamino, a 5- or 6-membered saturated nitrogen-containing heterocycle; X and Y are oxygen; Z is CH; m, p and q are, independently, an integer from 0 to 5, and n an integer from 1 to 5, as well as pharmaceutically acceptable salts thereof which are useful in the control of inflammatory, immunological, oncological, bronchopulmonary or cardiovascular disorders.

  公式的化合物，其中R是氢或羟基，R1和R2共同构成组--(CH2)m--，R7是氢或R1和R7共同构成组--(CH2)n--，且R2是氢；R3是一种芳香族或芳香杂环群；R4、R5和R6各自独立地为氢、卤素、烷基、羟基、烷氧基、卤代烷基、硝基、氨基、酰氨基、烷基硫醚、烷基亚磺酰基或烷基磺酰基；R8是组--(CH2)p--R9或--(CH2)q--R10；R9是氢、烷基碳酰基、氨基烷基碳酰基、氰基、脒基、烷氧基碳酰基、芳氧基碳酰基、烷基磺酰基、氨基甲酰基或硫代氨基甲酰基；R10是羟基、烷氧基、卤素、氨基、一烷基胺、二烷基胺、三烷基胺、叠氮基、酰氨基、烷基磺酰氨基、一个5或6成员的饱和含氮杂环；X和Y是氧；Z是CH；m、p和q各自独立地为0到5的整数，n为1到5的整数，以及作为药物可接受的盐，其在控制炎症、免疫、肿瘤、支气管肺或心血管疾病方面是有用的。
• Substituierte Pyrrole
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0384349A1

  公开（公告）日：1990-08-29

  Die Pyrrolderivate der Formel worin R¹ bis R⁸, R, X, Y und m die in der Beschreibung angegebene Bedeutung haben, sind therapeutisch aktive Sub­stanzen, insbesondere zur Verwendung als antiinflamma­torisch, immunologisch, onkologisch, bronchopulmonär und kardiovaskulär aktive Substanzen oder als Wirkstoffe in der Behandlung von Asthma oder AIDS. Sie werden hergestellt aus entsprechenden Furandion­derivaten, worin O für =N-R, X und Y steht.

  式中的吡咯衍生物 其中 R¹ 至 R⁸、R、X、Y 和 m 具有说明中给出的含义，是具有治疗活性的物质，特别是可用作抗炎、免疫、肿瘤、支气管和心血管活性物质或治疗哮喘或艾滋病的活性物质。 它们由相应的呋喃二酮衍生物制得，其中 O 代表 =N-R、X 和 Y。
• Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction
  作者：Rino A. Bit、Peter D. Davis、Lucy H. Elliott、William Harris、Christopher H. Hill、Elizabeth Keech、Hari Kumar、Geoffrey Lawton、Anna Maw、John S. Nixon、David R. Vesey、Julie Wadsworth、Sandra E. Wilkinson

  DOI：10.1021/jm00053a003

  日期：1993.1

  The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competitive inhibitors of improved potency and selectivity. Two compounds have been further evaluated and were shown to inhibit PKC of human origin and prevent T-cell activation in a human allogeneic mixed lymphocyte reaction. One of these compounds was orally absorbed in mice and antagonized a phorbol ester induced paw edema in a dose-dependent manner. This compound also selectively inhibited the secondary T-cell mediated response in a developing adjuvant arthritis model in rats and provides evidence for the potential use of PKC inhibitors as therapeutic immunomodulators.